Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
This is a prospective, open-label, single-center clinical study, to evaluate the efficacy and safety of Capecitabine combined with Lenvatinib and Tislelizumab as adjuvant treatment after resection in patients with biliary tract cancer.
Biliary Tract Cancer
DRUG: Capecitabine combined with lenvatinib and tislelizumab
1 year DFS rate, one year disease free survival rate, 12 month
2 years DFS rate, two years disease free survival rate, 24 month|1 year OS rate, one year overall survival rate, 12 month|3 years OS rate, three years overall survival rate, 36 month|AE, adverse event, 30 days from the beginning of treatment to the last treatment
This is a prospective, open-label, single-center clinical study, to evaluate the efficacy and safety of Capecitabine combined with Lenvatinib and Tislelizumab as adjuvant treatment after resection in patients with biliary tract cancer.